Davunetide

Davunetide
Identifiers
  • (2S)-5-amino-2-[[(2S)-1-[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2,4-diamino-4-oxobutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid
CAS Number
PubChem CID
Chemical and physical data
FormulaC36H60N10O12
Molar mass824.934 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC(=O)[C@H](CC(=O)N)N
  • InChI=1S/C36H60N10O12/c1-6-18(4)28(35(56)46-14-8-9-23(46)31(52)41-21(36(57)58)11-12-25(38)48)44-30(51)22(16-47)42-33(54)27(17(2)3)43-32(53)24-10-7-13-45(24)34(55)19(5)40-29(50)20(37)15-26(39)49/h17-24,27-28,47H,6-16,37H2,1-5H3,(H2,38,48)(H2,39,49)(H,40,50)(H,41,52)(H,42,54)(H,43,53)(H,44,51)(H,57,58)/t18-,19-,20-,21-,22-,23-,24-,27-,28-/m0/s1
  • Key:DWLTUUXCVGVRAV-XWRHUKJGSA-N

Davunetide (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, CP201) is a octapeptide derivative with the amino acid sequence NAPVSIPQ. It has antiinflammatory and neuroprotective effects and has been investigated for several conditions including schizophrenia and Alzheimer's Disease.[1][2][3][4][5][6][7]

References

  1. ^ Gozes I (2011). "NAP (davunetide) provides functional and structural neuroprotection". Current Pharmaceutical Design. 17 (10): 1040–1044. doi:10.2174/138161211795589373. PMID 21524250.
  2. ^ Gozes I (January 2017). "Sexual divergence in activity-dependent neuroprotective protein impacting autism, schizophrenia, and Alzheimer's disease". Journal of Neuroscience Research. 95 (1–2): 652–660. doi:10.1002/jnr.23808. PMID 27870441.
  3. ^ Gozes I (2020). "The ADNP Syndrome and CP201 (NAP) Potential and Hope". Frontiers in Neurology. 11 608444. doi:10.3389/fneur.2020.608444. PMC 7732499. PMID 33329371.
  4. ^ Ivashko-Pachima Y, Gozes I (2021). "Activity-dependent neuroprotective protein (ADNP)-end-binding protein (EB) interactions regulate microtubule dynamics toward protection against tauopathy". Progress in Molecular Biology and Translational Science. 177: 65–90. doi:10.1016/bs.pmbts.2020.07.008. ISBN 978-0-12-824143-1. PMID 33453943.
  5. ^ D'Amico AG, Maugeri G, Musumeci G, Reglodi D, D'Agata V (August 2021). "PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy". Journal of Molecular Neuroscience. 71 (8): 1525–1535. doi:10.1007/s12031-020-01769-4. PMID 33403597.
  6. ^ Bhargava S, Kulkarni R, Dewangan B, Kulkarni N, Jiaswar C, Kumar K, et al. (November 2023). "Microtubule stabilising peptides: new paradigm towards management of neuronal disorders". RSC Medicinal Chemistry. 14 (11): 2192–2205. doi:10.1039/d3md00012e. PMC 10650357. PMID 37974959.
  7. ^ Galushkin A, Gozes I (May 2025). "Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity". Advanced Drug Delivery Reviews. 220 115573. doi:10.1016/j.addr.2025.115573. PMID 40185278.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.